Camille C.
- Country
- France
- Department
- Service d'Oncologie Médicale
Research Overview
- Phase II Trial of Durvalumab, Olaparib, and Fulvestrant in ER-Positive, HER2-Negative Metastatic Breast Cancer with BRCA or HRR Gene Alterations
- Evaluation of Palbociclib Combined with Endocrine Therapy in ER+/HER2- Metastatic Breast Cancer Using Circulating DNA ESR1 Mutation Monitoring
- Evaluation of Reduced Duration of Adjuvant Endocrine Therapy with Exemestane, Anastrozole, and Letrozole in Postmenopausal Women with Low-Risk HR+ HER2- Breast Cancer
Data & Insights
Has run more than one trial at 109 of 336 partner sites.
Specializations
Breast Cancer Therapeutics
The investigator specializes in treating various forms of breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative disease states.
- Metastatic breast cancer management
- Early-stage breast cancer treatment
- Inflammatory breast cancer
Their research encompasses both localized and advanced disease presentations.
Targeted Therapies
The investigator focuses on innovative therapeutic approaches using targeted molecular treatments and immunotherapy combinations.
- PARP inhibitor therapy
- CDK4/6 inhibitor applications
- Hormone therapy optimization
Their work includes evaluation of novel drug combinations and treatment strategies.
Precision Medicine
The investigator specializes in biomarker-driven treatment approaches and personalized therapy selection.
- BRCA mutation therapy
- ESR1 mutation detection
- HER2 targeted approaches
Their research integrates molecular diagnostics with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.